Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17486219 | 0.87 | ALDH1A1 (0.35) | SMN1; SMN2ALDH1A1MAPTMAPK1HTT | |
| SCHEMBL17486283 | 0.82 | IDO1 (0.35) | SMN1; SMN2ALDH1A1MAPTMAPK1HTT | |
| SCHEMBL17486226 | 0.81 | RARA (0.37) | SMN1; SMN2ALDH1A1MAPTMAPK1HTT | |
| SCHEMBL17486286 | 0.81 | CYP11B1 (0.35) | SMN1; SMN2ALDH1A1MAPTMAPK1HTT | |
| SCHEMBL17486017 | 0.80 | SMN1; SMN2 (0.33) | SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL17477823 | 0.77 | NPC1 (0.38) | SMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL17486164 | 0.76 | PDGFRB (0.33) | — | |
| SCHEMBL17486158 | 0.76 | DGAT1 (0.37) | — | |
| SCHEMBL19295077 | 0.76 | ALOX5AP (0.33) | — | |
| SCHEMBL10472664 | 0.76 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1MAPTMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3174890-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-03-13 | — | — | EP | disclosed |
| US-9853228-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-26 | — | — | US | disclosed |
| US-9853228-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-26 | — | — | US | disclosed |
| US-20170250353-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-08-31 | — | — | US | disclosed |
| US-20170250353-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-08-31 | — | — | US | disclosed |
| WO-2016015815-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170250353-A1 | METAL COMPLEXES | SOD1, AP1M1, AP3M1 | SMN1; SMN2 3736/4885ALDH1A1 3721/4885MAPT 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.